Assess the incidence of mutations in the tyrosine kinase domain of the endothelial growth factor receptor in UK patients with newly diagnosed metastatic or recurrent non-small cell lung cancer and to investigate the quality of life of these patients undergoing first-line therapy with erlotinib.

Trial Profile

Assess the incidence of mutations in the tyrosine kinase domain of the endothelial growth factor receptor in UK patients with newly diagnosed metastatic or recurrent non-small cell lung cancer and to investigate the quality of life of these patients undergoing first-line therapy with erlotinib.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2010

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top